The 6 most recent market catalysts affecting $CNTB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bearish
Impact 65
Oppenheimer Maintains Outperform on Connect Biopharma Hldgs, Lowers Price Target to $5
Oppenheimer's analyst Mazahir Alimohamed maintained an 'Outperform' rating for Connect Biopharma Holdings (CNTB), signaling continued confidence in the company's long-term prospect…
Sep 15, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Connect Biopharma Hldgs, Maintains $10 Price Target
The filing indicates that BTIG analyst Julian Harrison has reaffirmed a 'Buy' rating and a $10 price target for Connect Biopharma Holdings (CNTB). This is a routine analyst action …
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 95
Connect Biopharma Holdings shares are trading lower after the company announced topline results from its global phase 2 study evaluating rademikibart. The endpoint did not reach statistical significance.
The failure of a Phase 2 clinical trial for a lead drug candidate is a major negative catalyst for a biotechnology company. This directly impacts Connect Biopharma's valuation as t…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 75
UPDATE: Connect Biopharma's Interim Topline Data from Phase 2 Study Shows Rademikibart Reduced Treatment Failure Rate At 28 Days By 66% (Though This Endpoint Did Not Reach Statistical Significance) And Improved Lung Function Vs. Placebo
This headline is a significant corporate catalyst for Connect Biopharma. The 66% reduction in treatment failure is a strong signal of efficacy, which could be very positive for the…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 75
Connect Biopharma's Interim Topline Data from Phase 2 Study Shows Rademikibart Reduced Treatment Failure Rate at 28 Days by 66% and Improved Lung Function Vs. Placebo
Connect Biopharma released interim topline data from its Phase 2 Seabreeze STAT asthma trial for rademikibart, an anti-IL-4Rα antibody. The key findings include a statistically sig…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 75
Connect Biopharma Hldgs Q2 EPS $(0.27) Beats $(0.31) Estimate, Sales $2.768M Beat $650.000K Estimate
This headline indicates a significant positive catalyst for Connect Biopharma Holdings (CNTB). Beating both EPS and sales estimates by a considerable margin suggests better-than-ex…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.